|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Company** | **Ticker** | **Industry** | **Quality** | **PAR** |
| Teva Pharma | TEVA | [Drug (Generic)](http://www.manifestinvesting.com/auth/quality_return.pl?industry_id=241&rm=browse_industry) | 79.5 | 14.0% |
|  | | | | |
| Current Price (11/05) | | | $50.77 | |
| CAPS Rating ([Rate this stock on CAPS](http://caps.fool.com/Ticker.aspx?ticker=TEVA)) | | | http://www.manifestinvesting.com/static/images/foolcaps_5.gif | |
|  | | | | |
| **Expected Income Statement** | | | | |
| Current Sales | | | 15,455.0 | |
| Sales Growth Forecast | | | 9.0% | |
| Net Profit Margin | | | 28.0% | |
|  | | | | |
| Projected Shares Outstanding | | | 918.0 | |
| EPS - Five Year Forecast | | | $7.26 | |
| Average P/E Ratio | | | 13.0 | |
| Projected Average Price | | | $94.41 | |
|  | | | | |
| Price Appreciation (Annualized) | | | 13.2% | |
| Annual Dividend Yield | | | 0.8% | |
| Projected Annual Return | | | 14.0% | |
|  | | | | |
| **Quality** | | | | |
| Financial Strength | | | 88 | 22.0 |
| EPS Stability | | | 88 | 22.0 |
| Industry Sales Growth Rate | | | 10.7% | 10.5 |
| Industry Net Profit Margin | | | 12.3% | 25.0 |
| Calculated Quality Rating | | | 79.5 | |
|  | | | | |
| **Fool CAPS** | | | | |
| **Total Players**  1876 Outperforms  63 Underperforms    **All-Stars**  531 Outperforms (98.3%)  9 Underperforms | | | | |
|  | | | | |
| Fundamental Data Updated: 10/15/2010 | | | | |